ID   HuT 102
AC   CVCL_3526
SY   HUT 102; Hut 102; HuT-102; Hut-102; HUT-102; HuT102; Hut102; HUT102; NCI-H102
DR   CLO; CLO_0004303
DR   CLDB; cl1776
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; TIB-162
DR   BioSample; SAMN03471941
DR   BioSample; SAMN10987657
DR   cancercelllines; CVCL_3526
DR   CCRID; 1101HUM-PUMC000468
DR   CCRID; 1102HUM-NIFDC00031
DR   CCTCC; GDC0051
DR   Cell_Model_Passport; SIDM01734
DR   Cosmic; 850197
DR   Cosmic; 933552
DR   Cosmic; 2361371
DR   DepMap; ACH-000612
DR   GEO; GSE168554
DR   GEO; GSM887153
DR   GEO; GSM888225
DR   IARC_TP53; 27004
DR   IPD-IMGT/HLA; 10777
DR   KCLB; 90102
DR   LiGeA; CCLE_120
DR   Lonza; 99
DR   PharmacoDB; HuT102_646_2019
DR   Progenetix; CVCL_3526
DR   RCB; RCB1979
DR   TKG; TKG 0382
DR   Wikidata; Q54896907
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2985879;
RX   PubMed=3001699;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6244013;
RX   PubMed=6261256;
RX   PubMed=6272125;
RX   PubMed=6954533;
RX   PubMed=6975346;
RX   PubMed=7662981;
RX   PubMed=8127147;
RX   PubMed=8547074;
RX   PubMed=8641406;
RX   PubMed=8806089;
RX   PubMed=8806090;
RX   PubMed=8806092;
RX   PubMed=8957066;
RX   PubMed=9738977;
RX   PubMed=9787181;
RX   PubMed=12920029;
RX   PubMed=15638862;
RX   PubMed=17170727;
RX   PubMed=19220422;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=26696625;
RX   PubMed=28357668;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=34794206;
WW   http://www.bmj.com/rapid-response/2011/10/30/cell-lines-hut102-and-hut78
WW   https://www.atcc.org/en/support/technical-support/faqs/hut-102-atcc-tib-162-cell-growth
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
CC   Population: African American.
CC   Doubling time: 38 hours (PubMed=6244013).
CC   HLA typing: A*66:02 (IPD-IMGT/HLA=10777).
CC   Transformant: NCBI_TaxID; 11908; Human T-lymphotropic virus 1 (HTLV-1).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=84.86%; Native American=0.23%; East Asian, North=1.93%; East Asian, South=0%; South Asian=0%; European, North=6.73%; European, South=6.25% (PubMed=30894373).
CC   Anecdotal: This is the cell line that was used by Gallo's lab to isolate HTLV-1 (PubMed=26696625).
CC   Caution: Indicated as originating from a 28 year old at sampling in PubMed=6261256, 26 year old in PubMed=6244013 and 29 year old in PubMed=8806092.
CC   Discontinued: ATCC; TIB-162; probable.
CC   Discontinued: KCLB; 90102; probable.
CC   Discontinued: RCB; RCB1979; true.
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000027.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC; CCRID; PubMed=28357668
ST   Amelogenin: X,Y
ST   CSF1PO: 8,11
ST   D12S391: 16,19
ST   D13S317: 11,13
ST   D16S539: 12
ST   D18S51: 20
ST   D19S433: 14
ST   D21S11: 28,29
ST   D2S1338: 19,23
ST   D3S1358: 15,16
ST   D5S818: 8,13
ST   D6S1043: 11,18
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   FGA: 24
ST   Penta D: 8,10
ST   Penta E: 7,8
ST   TH01: 7,8
ST   TPOX: 6
ST   vWA: 16,19
DI   NCIt; C3246; Mycosis fungoides
DI   ORDO; Orphanet_2584; Classic mycosis fungoides
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_B7GH ! CTCL-3
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3001699; DOI=10.1073/pnas.82.24.8359;
RA   Kiyokawa T., Seiki M., Iwashita S., Imagawa K., Shimizu F.,
RA   Yoshida M.;
RT   "p27x-III and p21x-III, proteins encoded by the pX sequence of human
RT   T-cell leukemia virus type I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:8359-8363(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6244013; DOI=10.1182/blood.V55.3.409.409;
RA   Gazdar A.F., Carney D.N., Bunn P.A. Jr., Russell E.K., Jaffe E.S.,
RA   Schechter G.P., Guccion J.G.;
RT   "Mitogen requirements for the in vitro propagation of cutaneous T-cell
RT   lymphomas.";
RL   Blood 55:409-417(1980).
//
RX   PubMed=6261256; DOI=10.1073/pnas.77.12.7415;
RA   Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A. Jr., Minna J.D.,
RA   Gallo R.C.;
RT   "Detection and isolation of type C retrovirus particles from fresh and
RT   cultured lymphocytes of a patient with cutaneous T-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:7415-7419(1980).
//
RX   PubMed=6272125; DOI=10.1038/294268a0;
RA   Poiesz B.J., Ruscetti F.W., Reitz M.S. Jr., Kalyanaraman V.S., Gallo R.C.;
RT   "Isolation of a new type C retrovirus (HTLV) in primary uncultured
RT   cells of a patient with Sezary T-cell leukaemia.";
RL   Nature 294:268-271(1981).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=6975346; DOI=10.1084/jem.154.5.1403;
RA   Gootenberg J.E., Ruscetti F.W., Mier J.W., Gazdar A.F., Gallo R.C.;
RT   "Human cutaneous T cell lymphoma and leukemia cell lines produce and
RT   respond to T cell growth factor.";
RL   J. Exp. Med. 154:1403-1418(1981).
//
RX   PubMed=7662981; DOI=10.1182/blood.V86.6.2350.bloodjournal8662350;
RA   Imada K., Takaori-Kondo A., Akagi T., Shimotohno K., Sugamura K.,
RA   Hattori T., Yamabe H., Okuma M., Uchiyama T.;
RT   "Tumorigenicity of human T-cell leukemia virus type I-infected cell
RT   lines in severe combined immunodeficient mice and characterization of
RT   the cells proliferating in vivo.";
RL   Blood 86:2350-2357(1995).
//
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
//
RX   PubMed=8806089; DOI=10.1002/jcb.240630502;
RA   Gazdar A.F., Minna J.D.;
RT   "NCI series of cell lines: an historical perspective.";
RL   J. Cell. Biochem. 63 Suppl. 24:1-11(1996).
//
RX   PubMed=8806090; DOI=10.1002/jcb.240630503;
RA   Bunn P.A. Jr., Foss F.M.;
RT   "T-cell lymphoma cell lines (HUT102 and HUT78) established at the
RT   National Cancer Institute: history and importance to understanding the
RT   biology, clinical features, and therapy of cutaneous T-cell lymphomas
RT   (CTCL) and adult T-cell leukemia-lymphomas (ATLL).";
RL   J. Cell. Biochem. 63 Suppl. 24:12-23(1996).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=12920029; DOI=10.1182/blood-2003-04-1043;
RA   Chung H.-K., Young H.A., Goon P.K.C., Heidecker G., Princler G.L.,
RA   Shimozato O., Taylor G.P., Bangham C.R.M., Derse D.D.;
RT   "Activation of interleukin-13 expression in T cells from
RT   HTLV-1-infected individuals and in chronically infected cell lines.";
RL   Blood 102:4130-4136(2003).
//
RX   PubMed=15638862; DOI=10.1111/j.1365-2141.2004.05289.x;
RA   Hasegawa H., Yamada Y., Harasawa H., Tsuji T., Murata K., Sugahara K.,
RA   Tsuruda K., Ikeda S., Imaizumi Y., Tomonaga M., Masuda M., Takasu N.,
RA   Kamihira S.;
RT   "Sensitivity of adult T-cell leukaemia lymphoma cells to tumour
RT   necrosis factor-related apoptosis-inducing ligand.";
RL   Br. J. Haematol. 128:253-265(2005).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=19220422; DOI=10.1111/j.1600-0609.2009.01211.x;
RA   Kamihira S., Terada C., Sasaki D., Yanagihara K., Tsukasaki K.,
RA   Hasegawa H., Yamada Y.;
RT   "Aberrant p53 protein expression and function in a panel of
RT   hematopoietic cell lines with different p53 mutations.";
RL   Eur. J. Haematol. 82:301-307(2009).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=26696625; DOI=10.1073/pnas.1521629112;
RA   Coffin J.M.;
RT   "The discovery of HTLV-1, the first pathogenic human retrovirus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:15525-15529(2015).
//
RX   PubMed=28357668; DOI=10.1007/978-1-4939-6872-5_11;
RA   Raimondi V., Minuzzo S.A., Ciminale V., D'Agostino D.M.;
RT   "STR profiling of HTLV-1-infected cell lines.";
RL   Methods Mol. Biol. 1582:143-154(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=34794206; DOI=10.1111/cas.15204;
RA   Ikebe E., Shimosaki S., Hasegawa H., Iha H., Tsukamoto Y., Wang Y.,
RA   Sasaki D., Imaizumi Y., Miyazaki Y., Yanagihara K., Hamaguchi I.,
RA   Morishita K.;
RT   "TAS-116 (pimitespib), a heat shock protein 90 inhibitor, shows
RT   efficacy in preclinical models of adult T-cell leukemia.";
RL   Cancer Sci. 113:684-696(2022).
//